These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11083629)

  • 21. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.
    Roblin PM; Hammerschlag MR
    Int J Antimicrob Agents; 2000 Sep; 16(1):61-3. PubMed ID: 11185415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Damage/Danger Associated Molecular Patterns (DAMPs) Modulate Chlamydia pecorum and C. trachomatis Serovar E Inclusion Development In Vitro.
    Leonard CA; Schoborg RV; Borel N
    PLoS One; 2015; 10(8):e0134943. PubMed ID: 26248286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro activity of fleroxacin against Chlamydia trachomatis.
    Steele-Mortimer O; Meier-Ewert H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():65-70. PubMed ID: 3144551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Commonly prescribed β-lactam antibiotics induce C. trachomatis persistence/stress in culture at physiologically relevant concentrations.
    Kintner J; Lajoie D; Hall J; Whittimore J; Schoborg RV
    Front Cell Infect Microbiol; 2014; 4():44. PubMed ID: 24783061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro susceptibility of 7.5-kb common plasmid-free Chlamydia trachomatis strains.
    Miyashita N; Matsumoto A; Matsushima T
    Microbiol Immunol; 2000; 44(4):267-9. PubMed ID: 10832970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.
    Donati M; Di Francesco A; D'Antuono A; Delucca F; Shurdhi A; Moroni A; Baldelli R; Cevenini R
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5379-80. PubMed ID: 20855744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.
    Chaudhry AZ; Knapp CC; Sierra-Madero J; Washington JA
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1843-5. PubMed ID: 2285304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.
    Song A; McCulley TJ; Lam BL; Feuer WJ; Miller D; Alfonso EC
    Am J Ophthalmol; 2001 Jun; 131(6):795-6. PubMed ID: 11384579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of clinically relevant culture conditions on antimicrobial susceptibility of Chlamydia trachomatis.
    Wyrick PB; Davis CH; Raulston JE; Knight ST; Choong J
    Clin Infect Dis; 1994 Nov; 19(5):931-6. PubMed ID: 7893882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
    Yokoi S; Yasuda M; Ito S; Takahashi Y; Ishihara S; Deguchi T; Maeda S; Kubota Y; Tamaki M; Fukushi H
    J Infect Chemother; 2004 Oct; 10(5):262-7. PubMed ID: 16163459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of ofloxacin against Chlamydia trachomatis.
    Schachter J; Moncada JV
    Am J Med; 1989 Dec; 87(6C):14S-16S. PubMed ID: 2690615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic dormancy in
    Rockey DD; Wang X; Debrine A; Grieshaber N; Grieshaber SS
    Infect Immun; 2024 Feb; 92(2):e0033923. PubMed ID: 38214508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of ciprofloxacin against clinical isolates of Chlamydia trachomatis.
    Meier-Ewert H; Weil G; Millott G
    Eur J Clin Microbiol; 1984 Aug; 3(4):372. PubMed ID: 6593220
    [No Abstract]   [Full Text] [Related]  

  • 35. In vitro analysis of the change in resistance of Chlamydia trachomatis under exposure to sub-MIC levofloxacin for a therapeutic term.
    Takahashi S; Hagiwara T; Shiga S; Takaoki Hirose T; Tsukamoto T
    Chemotherapy; 2000; 46(6):402-7. PubMed ID: 11053906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis.
    Nakata K; Maeda H; Fujii A; Arakawa S; Umezu K; Kamidono S
    Antimicrob Agents Chemother; 1992 Jan; 36(1):188-90. PubMed ID: 1317145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of in vitro activity of rokitamycin against Chlamydia trachomatis].
    Bannai H; Miyano A; Miyazawa H; Ashihara Y
    Kansenshogaku Zasshi; 1990 Jun; 64(6):687-92. PubMed ID: 2401815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of standard proportion dilution test and Etest for Mycobacterium tuberculosis sensitivity to ofloxacin and ciprofloxacin].
    Cavuşoğlu C; Ciçek-Saydam C; Burhanoğlu D; Ozkalay N; Ozkaya D; Ozçam H; Bilgiç A
    Mikrobiyol Bul; 2002 Jan; 36(1):118-23. PubMed ID: 12476777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antichlamydial activity of ofloxacin.
    Hirai K; Une T
    Microbiol Immunol; 1986; 30(5):445-50. PubMed ID: 3462450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens.
    Eiferman RA
    Cornea; 2001 May; 20(4):438-9. PubMed ID: 11333340
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.